122 related articles for article (PubMed ID: 37753656)
1. Regional Social Vulnerability is Associated With Geographic Disparity in Waitlist Outcomes for Patients With Non-Hepatocellular Carcinoma Model for End-stage Liver Disease Exceptions in the United States.
Cannon RM; Goldberg DS; Sheikh SS; Anderson DJ; Pozo M; Rabbani U; Locke JE
Ann Surg; 2024 May; 279(5):825-831. PubMed ID: 37753656
[TBL] [Abstract][Full Text] [Related]
2. Impact of major hepatocellular carcinoma policy changes on liver transplantation for hepatocellular carcinoma in the United States.
Shah RH; Chyou D; Goldberg DS
Liver Transpl; 2022 Dec; 28(12):1857-1864. PubMed ID: 35585774
[TBL] [Abstract][Full Text] [Related]
3. Regional Variation in Appropriateness of Non-Hepatocellular Carcinoma Model for End-Stage Liver Disease Exception.
Cannon RM; Davis EG; Goldberg DS; Lynch RJ; Shah MB; Locke JE; McMasters KM; Jones CM
J Am Coll Surg; 2020 Apr; 230(4):503-512.e8. PubMed ID: 32007535
[TBL] [Abstract][Full Text] [Related]
4. Increasing disparity in waitlist mortality rates with increased model for end-stage liver disease scores for candidates with hepatocellular carcinoma versus candidates without hepatocellular carcinoma.
Goldberg D; French B; Abt P; Feng S; Cameron AM
Liver Transpl; 2012 Apr; 18(4):434-43. PubMed ID: 22271656
[TBL] [Abstract][Full Text] [Related]
5. Excess mortality on the liver transplant waiting list: unintended policy consequences and Model for End-Stage Liver Disease (MELD) inflation.
Northup PG; Intagliata NM; Shah NL; Pelletier SJ; Berg CL; Argo CK
Hepatology; 2015 Jan; 61(1):285-91. PubMed ID: 24995689
[TBL] [Abstract][Full Text] [Related]
6. HCC patients suffer less from geographic differences in organ availability.
Schuetz C; Dong N; Smoot E; Elias N; Schoenfeld DA; Markmann JF; Yeh H
Am J Transplant; 2013 Nov; 13(11):2989-95. PubMed ID: 24011291
[TBL] [Abstract][Full Text] [Related]
7. MELD Exceptions and Rates of Waiting List Outcomes.
Massie AB; Caffo B; Gentry SE; Hall EC; Axelrod DA; Lentine KL; Schnitzler MA; Gheorghian A; Salvalaggio PR; Segev DL
Am J Transplant; 2011 Nov; 11(11):2362-71. PubMed ID: 21920019
[TBL] [Abstract][Full Text] [Related]
8. Effect of Mandatory 6-Month Waiting Period on Waitlist and Transplant Outcomes in Patients With Hepatocellular Carcinoma.
Nagai S; Kitajima T; Yeddula S; Salgia R; Schilke R; Abouljoud MS; Moonka D
Hepatology; 2020 Dec; 72(6):2051-2062. PubMed ID: 32157711
[TBL] [Abstract][Full Text] [Related]
9. The Effect of Acuity Circles on Deceased Donor Transplant and Offer Rates Across Model for End-Stage Liver Disease Scores and Exception Statuses.
Wey A; Noreen S; Gentry S; Cafarella M; Trotter J; Salkowski N; Segev D; Israni A; Kasiske B; Hirose R; Snyder J
Liver Transpl; 2022 Mar; 28(3):363-375. PubMed ID: 34482614
[TBL] [Abstract][Full Text] [Related]
10. Travel distance and social vulnerability index: Impact on liver-related mortality among patients with end-stage liver disease.
Yang J; Endo Y; Moazzam Z; Lima HA; Woldesenbet S; Alaimo L; Azap L; Shaikh CF; Munir MM; Katayama E; Sasaki K; Pawlik TM
Clin Transplant; 2023 Sep; 37(9):e15001. PubMed ID: 37126400
[TBL] [Abstract][Full Text] [Related]
11. Delayed hepatocellular carcinoma model for end-stage liver disease exception score improves disparity in access to liver transplant in the United States.
Heimbach JK; Hirose R; Stock PG; Schladt DP; Xiong H; Liu J; Olthoff KM; Harper A; Snyder JJ; Israni AK; Kasiske BL; Kim WR
Hepatology; 2015 May; 61(5):1643-50. PubMed ID: 25644186
[TBL] [Abstract][Full Text] [Related]
12. Characterizing the Risk of False-Positive Hepatocellular Carcinoma in Recipients Transplanted With T2 MELD Exceptions.
Bittermann T; Goldberg DS; Bauer CM; Khungar V
Transplantation; 2017 May; 101(5):1099-1105. PubMed ID: 28121908
[TBL] [Abstract][Full Text] [Related]
13. Inequity in organ allocation for patients awaiting liver transplantation: Rationale for uncapping the model for end-stage liver disease.
Nadim MK; DiNorcia J; Ji L; Groshen S; Levitsky J; Sung RS; Kim WR; Andreoni K; Mulligan D; Genyk YS
J Hepatol; 2017 Sep; 67(3):517-525. PubMed ID: 28483678
[TBL] [Abstract][Full Text] [Related]
14. Center variation in the use of nonstandardized model for end-stage liver disease exception points.
Goldberg DS; Makar G; Bittermann T; French B
Liver Transpl; 2013 Dec; 19(12):1330-42. PubMed ID: 24039090
[TBL] [Abstract][Full Text] [Related]
15. MELDEQ : An alternative Model for End-Stage Liver Disease score for patients with hepatocellular carcinoma.
Marvin MR; Ferguson N; Cannon RM; Jones CM; Brock GN
Liver Transpl; 2015 May; 21(5):612-22. PubMed ID: 25694099
[TBL] [Abstract][Full Text] [Related]
16. Liver Transplant Waitlist Outcomes and the Allocation of Hepatocellular Carcinoma Model for End-Stage Liver Disease Exception Points at a Low-Volume Center.
Tan EK; Goh BKP; Lee SY; Krishnamoorthy TL; Tan CK; Jeyaraj PR
Transplant Proc; 2018 Dec; 50(10):3564-3570. PubMed ID: 30577239
[TBL] [Abstract][Full Text] [Related]
17. A novel waitlist dropout score for hepatocellular carcinoma - identifying a threshold that predicts worse post-transplant survival.
Mehta N; Dodge JL; Roberts JP; Yao FY
J Hepatol; 2021 Apr; 74(4):829-837. PubMed ID: 33188904
[TBL] [Abstract][Full Text] [Related]
18. Region 11 MELD Na exception prospective study.
Fisher RA; Heuman DM; Harper AM; Behnke MK; Smith AD; Russo MW; Zacks S; McGillicuddy JW; Eason J; Porayko MK; Northup P; Marvin MR; Hundley J; Nair S
Ann Hepatol; 2012; 11(1):62-7. PubMed ID: 22166562
[TBL] [Abstract][Full Text] [Related]
19. Model for End-Stage Liver Disease/Pediatric End-Stage Liver Disease exception policy and outcomes in pediatric patients with hepatopulmonary syndrome requiring liver transplantation.
Raza MH; Kwon Y; Kobierski P; Misra AC; Lim A; Goldbeck C; Etesami K; Kohli R; Emamaullee J
Liver Transpl; 2023 Feb; 29(2):134-144. PubMed ID: 35876731
[TBL] [Abstract][Full Text] [Related]
20. Comparison of two equivalent model for end-stage liver disease scores for hepatocellular carcinoma patients using data from the United Network for Organ Sharing liver transplant waiting list registry.
Alver SK; Lorenz DJ; Washburn K; Marvin MR; Brock GN
Transpl Int; 2017 Nov; 30(11):1098-1109. PubMed ID: 28403575
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]